Hosted on MSN5d
Denali Starts Dosing in Phase II Parkinson's Disease StudyDenali Therapeutics Inc. DNLI initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151). BIIB122, an ...
Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...
BEACON study is a phase IIa trial evaluating the company's investigational drug BIIB122 (DNL151), a selective LRRK2 inhibitor, for Parkinson's disease linked to LRRK2 mutations (LRRK2-PD).
Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...
The Phase 2a study is intended to evaluate safety and biomarkers associated with oral daily dosing of BIIB122 in approximately 50 participants with Parkinson’s disease and LRRK2 pathogenic ...
BIIB122 is also being investigated in the ongoing global Phase 2b LUMA study in participants with early-stage Parkinson’s disease with or without a LRRK2 mutation, in collaboration with Biogen.
Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback